Eli Lilly and Company ($LLY) Stock Forecast: Down 5.2% Today

What is Eli Lilly and Company?

Eli Lilly & Co (LLY) is a pharmaceutical company known for its innovative treatments in various therapeutic areas. Today, the stock experienced a strong bearish movement in the market.

Why is Eli Lilly and Company going down?

LLY stock is down 5.2% on Feb 5, 2026 15:27

• The bearish movement in Eli Lilly & Co (LLY) stock could be attributed to profit-taking by investors after a recent rally or market correction.
• Despite being identified as a promising growth stock with strong fundamentals, including earnings and sales growth, investors might have reacted to broader market sentiment or sector-specific concerns.
• The focus on pharmaceutical stocks like Eli Lilly & Co (LLY) could have shifted due to a stem cell specialist going public via a SPAC merger, drawing attention away from traditional pharmaceutical companies.
• Additionally, a positive stock price prediction for Waste Management and growth potential for Hershey might have diverted investor interest away from Eli Lilly & Co (LLY) temporarily, impacting its stock performance.

LLY Price Chart

LLY Technical Analysis

LLY News

Stem Cell Specialist PrimeGen Takes SPAC Track to Nasdaq

PrimeGen US, a stem cell specialist, is going public via a Special Purpose Acquisition Company (SPAC) merger with DT Cloud Star Acquisition Corporation. The deal values PrimeGen at $1.5 billion and will fund its preclinical pipeline of triple-activated mesenchymal stem cells for acute liver injury. This move highlights SPACs as an alternative route to the public market for biotechs, especially those yet to enter clinical trials.

https://www.biospace.com/business/stem-cell-specialist-primegen-takes-spac-track-to-nasdaq

Waste Management (NYSE: WM) Stock Price Prediction and Forecast 2026-2030 (Feb 2026)

This article provides a stock price prediction and forecast for Waste Management (NYSE: WM) shares through 2030, highlighting the company's competitive advantages and growth opportunities. Waste Management benefits from a dominant position in landfill ownership, expansion into medical waste disposal through Stericycle, and investments in renewable energy and recycling. 24/7 Wall St. projects a significant upside, with an estimated target price of $476.47 per share by 2030.

https://247wallst.com/forecasts/2026/02/05/waste-management-nyse-wm-stock-price-prediction-and-forecast-2025-2030/

After a 30% Rally, Here’s Why Hershey Stock Could Continue Its Momentum in 2026

Hershey stock, trading around $195, shows potential for continued growth, projected to reach $230 by December 2027, representing an 18% upside. This optimistic outlook is driven by a 20% increase in brand marketing spend, easing cocoa costs, and reduced tariff pressure, which are expected to stabilize volume and boost operating margins to 19% by 2026-2027. The company's stable brand position, consistent cash generation, and disciplined capital returns within a mature market, combined with conservative revenue growth and a stable P/E multiple, support this positive forecast.

https://www.tikr.com/blog/after-a-30-rally-heres-why-hershey-stock-could-continue-its-momentum-in-2026

Eli Lilly & Co (NYSE:LLY) Stands Out in Recent CANSLIM Growth Stock Screen

Eli Lilly & Co (NYSE:LLY) has been identified as a promising growth stock through a recent CANSLIM methodology screen, meeting several key criteria including strong quarterly earnings and sales growth, substantial annual EPS increases, and high return on equity. The company also demonstrates acceptable financial health, significant institutional sponsorship, and market leadership with a high relative strength rating. While its current valuation is noted as high and the technical buying point may require careful timing, LLY's robust fundamentals positioned within a favorable market direction make it a notable candidate for growth-oriented investors.

https://www.chartmill.com/news/LLY/Chartmill-41210-Eli-Lilly-Co-NYSELLY-Stands-Out-in-Recent-CANSLIM-Growth-Stock-Screen

Alphabet Earnings: Continued Momentum on Cloud and Search as Capital Expenses Set to Mount

Alphabet (GOOG) reported robust Q4 earnings with an 18% sales increase, primarily driven by its Google Cloud segment which saw 48% growth. The company successfully integrated AI into its Search product, mitigating competitive threats and boosting engagement. Despite strong results, Alphabet anticipates a significant increase in capital expenditures for 2026, projected at $180 billion, to support its full-stack AI strategy.

https://www.morningstar.com/stocks/alphabet-earnings-continued-momentum-cloud-search-capital-expenses-set-mount

Trending Today

Cummins Inc. ($CMI) Stock Forecast: Down 6.8% Today

fuboTV Inc. ($FUBO) Stock Forecast: Up 5.1% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 6.6% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.2% Today

QTUM ($QTUM) Crypto Forecast: Down 10.9% Today

MKS Instruments Inc. ($MKSI) Stock Forecast: Up 5.8% Today

Credo Technology Group ($CRDO) Stock Forecast: Up 5.5% Today

Quanta Services Inc. ($PWR) Stock Forecast: Up 5.1% Today

McKesson Corporation ($MCK) Stock Forecast: Up 13.6% Today

Upwork Inc. ($UPWK) Stock Forecast: Up 5.1% Today

Eli Lilly and Company Price History

03.01.2026 - LLY Stock was down 3.6%

• The promising Q4 revenue projections for Eli Lilly were overshadowed by the substantial investments in research and development. This financial strategy possibly instigated investor worries over the company's future profitability, contributing to the day's bearish market performance.
• Forecasts of positive stock momentum following the announcement of fresh data from Lilly's GLP-1 clinical trials failed to materialize as expected, potentially disappointing eager investors awaiting favorable outcomes.
• The noteworthy surge in institutional investors, with Peterson Wealth Services among them, signaled an optimistic long-term perspective on Eli Lilly. However, short-term profit-taking or apprehensions regarding R&D expenditures impacting immediate earnings might have influenced today's market downturn.

05.00.2026 - LLY Stock was down 3.6%

• The stock's decline could potentially be linked to a lawsuit filed by the Indiana Attorney General accusing the company of being part of a scheme to increase insulin prices. This legal issue and the resulting negative attention likely shook investor confidence in the company's financial strength and standing.
• Although Eli Lilly was previously identified as a promising AI-powered medical stock for 2026, the unfavorable news related to the lawsuit overshadowed any positive perceptions of the company's technological progress.
• Additionally, the decision by Eli Lilly to lower prices in China, a move aimed at strengthening its position in a competitive market, might have raised worries about the company's profits and overall revenue outlook, influencing the downward trend in the market.
• The setbacks faced by competitors like Ultragenyx Pharmaceutical and Mereo BioPharma in their clinical trials, which led to notable drops in their stock prices, could have contributed to a broader pessimistic sentiment in the pharmaceutical industry, thereby impacting Eli Lilly's stock performance.

15.00.2026 - LLY Stock was down 5.0%

• The decline in Eli Lilly's stock may be linked to competitive anxieties triggered by Novo Nordisk's oral GLP-1 and the associated short-term risks.
• Despite positive financial results and strategic efforts, the increased ownership by Eastern Bank and Ashton Thomas Securities LLC could not fully counterbalance concerns over the competitive environment.
• Legal actions taken by Dover Corp. against leading insulin manufacturers, including Eli Lilly, on allegations of pricing manipulation leading to elevated drug costs, could have contributed to the negative outlook on Eli Lilly's stock.
• In summary, today's bearish trend on Eli Lilly's stock likely stems from a mixture of competitive fears, legal issues within the pharmaceutical sector, and potential risks impacting investor confidence in the company's future prospects.

28.00.2026 - LLY Stock was down 5.2%

• Profit-taking by investors post a period of strong performance could be a reason behind the bearish movement in LLY's stock.
• Market sentiment might have been influenced by broader economic factors or sector rotation, despite positive news regarding a strategic partnership for genetic biotech treatments targeting hearing loss.
• The FDA granting Breakthrough Therapy Designation to a competitor for treating cutaneous lupus erythematosus (CLE) might have diverted investor attention away from LLY, impacting its stock performance.
• Competition in the pharmaceutical industry, exemplified by positive Phase II results for an obesity candidate by a competitor, may have also played a role in the bearish movement in LLY's stock.

07.00.2026 - LLY Stock was up 5.2%

• Eli Lilly's stock surged as reports surfaced about the company being in advanced talks to acquire Ventyx Biosciences, a move that could significantly expand its immunology portfolio.
• The prospective launches of cardiometabolic treatments by Eli Lilly, as projected by an industry analyst, have also contributed to investor optimism and confidence in the company's future revenue potential.
• The overall positive sentiment towards Eli Lilly's pipeline and potential acquisitions has likely fueled the bullish movement in the stock, showcasing investor enthusiasm for the company's growth prospects in the pharmaceutical market.

07.00.2026 - LLY Stock was up 5.4%

• Eli Lilly and Company (LLY) experienced a strong bullish movement following reports of advanced talks to acquire a biosciences company, showcasing market optimism for potential portfolio expansion and growth opportunities.
• The strategic initiatives by Eli Lilly and Company, including potential acquisitions and innovative treatments, have likely contributed to the positive market sentiment and bullish movement in the stock price.

04.01.2026 - LLY Stock was up 9.2%

• Eli Lilly's shares surged by 10% following the company's impressive fourth-quarter 2025 results and optimistic 2026 forecast, driven by the success of its weight-loss drugs Zepbound and Mounjaro.
• A Buy rating from Goldman Sachs for Eli Lilly further boosted investor confidence, highlighting the stock's attractiveness and maintaining a target price of USD 1145.
• The strong performance of Eli Lilly amidst a positive market reaction underscores the company's robust growth in the weight-loss drug market, setting a bullish tone for its future prospects.

11.11.2025 - LLY Stock was up 3.7%

• Eli Lilly's bullish movement can be attributed to the positive results from its obesity drug trial, showcasing the company's commitment to developing effective treatments.
• The removal of CVS from its employee drug plan following a drug snub highlights the competitive landscape in the pharmaceutical industry and Eli Lilly's strategic decisions to maintain market position.
• Market rumors of a potential takeover by Eli Lilly have also contributed to the stock's surge, indicating investor confidence in the company's growth strategy and potential acquisitions.
• Overall, Eli Lilly's strong performance reflects a combination of successful drug trials, strategic business decisions, and market speculations driving the stock's upward momentum.

05.01.2026 - LLY Stock was down 5.2%

• The bearish movement in Eli Lilly & Co (LLY) stock could be attributed to profit-taking by investors after a recent rally or market correction.
• Despite being identified as a promising growth stock with strong fundamentals, including earnings and sales growth, investors might have reacted to broader market sentiment or sector-specific concerns.
• The focus on pharmaceutical stocks like Eli Lilly & Co (LLY) could have shifted due to a stem cell specialist going public via a SPAC merger, drawing attention away from traditional pharmaceutical companies.
• Additionally, a positive stock price prediction for Waste Management and growth potential for Hershey might have diverted investor interest away from Eli Lilly & Co (LLY) temporarily, impacting its stock performance.

04.01.2026 - LLY Stock was up 5.4%

• Eli Lilly reported impressive Q4 results, surpassing revenue and profit expectations, driven by the success of its drugs Zepbound and Mounjaro, leading to a significant stock surge.
• The company's robust 2026 revenue guidance, exceeding analyst estimates, indicates strong growth prospects and market confidence in its product pipeline.
• Positive market sentiment towards Eli Lilly contrasts with concerns in the pharmaceutical sector, highlighted by Pfizer's modest 2026 guidance and sustainability worries regarding its dividend payout ratio.
• Eli Lilly's performance showcases the importance of consistent innovation and successful product launches in driving stock value, setting it apart from competitors like Novo Nordisk.

04.01.2026 - LLY Stock was up 8.8%

• LLY's stock surged by 10% following the company's better-than-expected Q4 2025 results and optimistic 2026 forecast, driven by the success of weight-loss drugs Zepbound and Mounjaro.
• The positive market reaction can be attributed to Lilly's robust revenue growth of 42.6% year-over-year and adjusted earnings per share exceeding analyst estimates.
• This bullish trend for LLY contrasts with Novo Nordisk's recent 15% stock drop due to a conservative sales outlook, highlighting the importance of strong performance and growth forecasts in the pharmaceutical industry.
• Analysts, such as those at Goldman Sachs, continue to view Eli Lilly favorably, maintaining a Buy rating amidst the company's impressive financial results and market outlook.

06.00.2026 - LLY Stock was up 1.4%

• Eli Lilly's upward trend aligns with the positive outlook in the healthcare sector, fueled by advancements in medical technology and drug development.
• Recognition of Eli Lilly's integration of AI for growth and innovation could have heightened investor confidence, as pointed out by industry analysts.
• Optimistic results from Alumis Inc.'s Phase 3 trial for a psoriasis drug likely contributed to the positive sentiment towards pharmaceutical firms like Eli Lilly, resulting in increased buying interest.
• Indirectly, Pfizer's announcement of price hikes for branded medications may have indicated revenue growth opportunities in the pharmaceutical industry, potentially bolstering Eli Lilly's stock performance.